Eric Yang, MD
Cardiovascular Disease · Los Angeles, CANPI 1205028644
Payments from drug & device makers
Across 174 payments — averaging $2011.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$174K
- Janssen Research & Development, LLC$82K
- Edwards Lifesciences$26K
- Amgen$24K
- Boehringer Ingelheim International GmbH$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
- plus $10K from 14 others
What the payments were for
- Consulting fees$23,23863%
- Speaking & faculty fees$7,99622%
- Travel & lodging$2,1746%
- Food & beverage$3,1759%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 77 | $174,374 |
| Janssen Research & Development, LLC | 18 | $81,849 |
| Edwards Lifesciences | 37 | $26,309 |
| Amgen | 3 | $24,066 |
| Boehringer Ingelheim International GmbH | 4 | $23,328 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $9,759 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $7,554 |
| Abbott | 10 | $926 |
| AstraZeneca | 4 | $713 |
| Medtronic(2 entities) | 3 | $288 |
| Abiomed | 3 | $254 |
| Philips North America LLC | 1 | $137 |
| Biotronik NRO, Inc. | 1 | $132 |
| Kestra Medical Technology Services, Inc. | 1 | $63 |
| Cleerly, Inc. | 1 | $56 |
| Boston Scientific | 1 | $52 |
| Atricure, Inc. | 1 | $37 |
| Novo Nordisk | 1 | $32 |
| Lantheus Medical Imaging, Inc. | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$349,970 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $195,979 |
| JardianceEmpagliflozin | 52 | $71,181 |
| EntrestoSacubitril/Valsartan | 55 | $70,645 |
| XareltoRivaroxaban | 29 | $37,038 |
| Repatha SureclickEvolocumab | 26 | $20,678 |
| Rosuvastatin Calcium | 358 | $6,800 |
| Valsartan | 93 | $4,262 |
| Metoprolol Succinate | 220 | $3,751 |
| Atorvastatin Calcium | 256 | $3,161 |
| Eplerenone | 28 | $2,148 |
| Potassium Chloride | 40 | $1,883 |
| Amlodipine Besylate | 187 | $1,463 |
| Ezetimibe | 71 | $1,406 |
| Carvedilol | 109 | $1,128 |
| Pravastatin Sodium | 64 | $1,068 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Los Angeles
- Kalyanam ShivkumarLos Angeles$2.9M
- Priscilla HsueLos Angeles$2.3M
- Cathleen Bairey-MerzLos Angeles$1.4M
- Somjot BrarLos Angeles$1.2M
- Freny ModyLos Angeles$960K
- Jamil AboulhosnLos Angeles$683K
- Parveen GargLos Angeles$653K
- Karol WatsonLos Angeles$553K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.